ADan amyloidosis is a very rare, inherited brain disease. It happens when a small protein fragment called “ADan” builds up as amyloid in the walls of brain blood vessels and in nearby brain tissue. This buildup damages vessels and nerves and slowly harms brain function. It is caused by a specific change (mutation) in the ITM2B gene (also called BRI2). People usually develop cataracts and hearing loss first, then balance and walking problems (ataxia), and later behavior changes and dementia. The disease shows a pattern called cerebral amyloid angiopathy, and ADan deposits can occur together with amyloid-beta in blood vessels. PMC+1Oxford AcademicScienceDirect
ADan amyloidosis is a very rare inherited brain and eye disease. A small protein called ADan (made from a gene called ITM2B/BRI2) builds up in blood vessel walls and brain tissue. Over time this harms the eyes (early cataracts), the ears (hearing loss), movement (cerebellar ataxia), and thinking and behavior (dementia/psychosis). It runs in families in an autosomal dominant way (a child has a 50% chance to inherit it from an affected parent). There is no proven cure yet. Care focuses on early diagnosis, safety, symptom control, and family counseling. PNASOxford AcademicMedlinePlusPMC
In ADan amyloidosis, a tiny “copying” mistake near the end of the ITM2B/BRI2 gene makes the BRI2 protein too long. The cell then cuts this extra tail into a 34–amino-acid piece called ADan. ADan easily sticks to itself and forms amyloid deposits around small brain and retinal vessels (cerebral/retinal amyloid angiopathy). BRI2 may also lose its normal nerve-protecting role at synapses, which adds to memory and movement problems. PNAS+1PMCNature
Other names
ADan amyloidosis is also called Familial Danish Dementia (FDD), ITM2B-related cerebral amyloid angiopathy type 2, and (historically) “heredopathia ophthalmo-oto-encephalica.” It belongs to the group of hereditary cerebral amyloid angiopathies and is caused by a duplication near the stop codon of the ITM2B/BRI2 gene that produces a longer C-terminal peptide (ADan) that forms amyloid. PMC+1
Types
Because the genetic cause is the same, doctors usually classify ADan amyloidosis by where and how the amyloid accumulates and what dominates clinically:
Vascular-predominant (CAA-dominant) form. The main problem is amyloid in brain and retinal vessel walls (cerebral amyloid angiopathy), leading to microbleeds or hemorrhage and stepwise brain injury. PMC
Mixed vascular + parenchymal form. ADan deposits occur in vessel walls and also in surrounding brain tissue, sometimes together with amyloid-beta; this mix can drive progressive cognitive decline. Oxford AcademicScienceDirect
Oculo-oto-cerebellar-predominant presentation. Early cataracts and hearing loss followed by prominent gait imbalance and ataxia, with dementia appearing later. PMCOrpha
Note: These “types” reflect clinical patterns seen in reports; they are not separate diseases—the same ITM2B mutation underlies them. PMC
Causes
Autosomal-dominant ITM2B (BRI2) mutation. A 10-nucleotide duplication just before the stop codon causes a frameshift and creates the amyloidogenic ADan peptide after furin cleavage—this is the root cause. PNASPMC
Production of 34-amino-acid ADan peptide. The mutant BRI2 yields a longer C-terminal fragment that aggregates as amyloid. PMCBioMed Central
Loss of normal BRI2 function at synapses. Mutant BRI2/ITM2B reduces BRI2 levels and impairs glutamatergic transmission and plasticity, promoting neurodegeneration. JBCPMC
Cerebral amyloid angiopathy (CAA). ADan deposits in vessel walls injure and weaken small arteries and arterioles, driving microbleeds and ischemia. PMC
Co-deposition with amyloid-β (Aβ). ADan frequently coexists with Aβ in vessels, which may worsen toxicity and clearance failure. Oxford AcademicScienceDirect
Failed perivascular clearance. Amyloid builds up when drainage of interstitial fluid along perivascular pathways fails. BioMed Central
Microvascular inflammation and injury. Amyloid-laden vessels show wall damage, hyalinization, and perivascular changes that impair blood flow. PMC
Protease processing imbalance. Furin and related convertases generate amyloidogenic fragments; abnormal processing promotes ADan production. BioMed Central
Interaction with Aβ pathways. BRI2 normally modulates Aβ deposition; mutation disturbs this balance, possibly increasing amyloid stress. Journal of Neuroscience
Oxidative stress from amyloid-injured vessels. Chronic hypoperfusion and microbleeds foster oxidative damage and white matter injury. thejcn.com
Synaptic dysfunction early in life. Animal models show early presynaptic defects that precede overt deposits. PMC
Age-related vulnerability of small vessels. As with other CAAs, age increases susceptibility to amyloid vascular disease. PubMed
Microglial activation. Microglia can contribute to processing of ITM2B fragments and inflammatory responses around deposits. SpringerLink
Blood–brain barrier (BBB) disruption. Amyloid in vessel walls weakens the BBB, promoting leakage and secondary injury. thejcn.com
White-matter small-vessel disease. Diffuse microvascular damage yields leukoencephalopathy and cognitive slowing. PMC
Retinal and optic-nerve vessel amyloidosis. Ocular vessel involvement contributes to early vision problems. Eye Disorders Database
Cranial-nerve demyelination (secondary). Chronic amyloid-related damage is associated with very thin, nearly demyelinated cranial nerves in reports. Wikipedia
Hemorrhagic complications. Lobar hemorrhage from CAA accelerates stepwise neurological decline. Eye Disorders Database
Genetic penetrance within families. The mutation is highly penetrant in affected kindreds, so many carriers develop disease. PNAS
Stop-loss/extension mechanism generality. Stop-loss mutations in ITM2B create amyloidogenic peptides (ADan/ABri), a shared molecular cause across related familial dementias. PMC
Common symptoms
1) Early cataracts. Clouding of the lens often appears in the 20s–30s and is a frequent first sign. PMCOrpha
2) Progressive hearing loss. Sensorineural hearing impairment follows ocular symptoms by 10–20 years and may become severe. Eye Disorders Database
3) Cerebellar ataxia. Balance and coordination decline with a wide-based gait, frequent falls, and difficulty with fine movements. PMC
4) Intention tremor. Tremor that worsens as the hand approaches a target reflects cerebellar pathway injury. Eye Disorders Database
5) Gait instability. Walking becomes unsteady due to cerebellar dysfunction and white-matter small-vessel disease. PMC
6) Visual impairment beyond cataract. Retinal and optic-nerve vessel disease can add vision problems. Eye Disorders Database
7) Paranoid psychosis or behavioral change. Delusions, paranoia, and later apathy or stereotyped behavior can appear. PMCWikipedia
8) Progressive dementia. Memory, speed of thinking, and executive skills decline over years. PMC
9) Headache or transient focal episodes. Vascular fragility and microbleeds may cause headaches or brief neurologic symptoms. PMC
10) Stroke or intracerebral hemorrhage. Lobar hemorrhage can occur and carry high risk. Eye Disorders Database
11) Speech and language difficulty. White-matter and cortical injury can slow speech or impair word-finding. PMC
12) Fine motor clumsiness. Tasks like buttoning or writing become hard due to cerebellar involvement. PMC
13) Mood and sleep problems. Anxiety, depression, and sleep disruption often track with neurodegeneration. (General in hereditary CAA.) PMC
14) Dysphagia (late). Swallowing can worsen in advanced disease during global decline. PMC
15) Increased falls and injuries. Ataxia plus visual and hearing loss raise fall risk. PMC
Diagnostic tests
A) Physical examination (bedside assessment)
1) Full neurologic exam. Checks strength, reflexes, sensation, eye movements, and coordination to map which brain systems are affected by small-vessel injury. PMC
2) Cerebellar testing at the bedside. Heel-to-shin, finger-to-nose, rebound, and rapid alternating movements show ataxia typical of this disease. PMC
3) Gait and balance evaluation. Tandem gait and Romberg help quantify instability and fall risk as the cerebellum and white matter are affected. PMC
4) Cognitive screening (MoCA/MMSE). Short tests flag early problems with memory, attention, and mental speed seen in hereditary CAA. PMC
5) Eye and ear examination. Slit-lamp exam for cataracts and otoscopic/audiologic checks for hearing loss document the early, characteristic features. OrphaEye Disorders Database
B) “Manual” or bedside functional tests
6) Bedside vision tests. Snellen chart and visual fields track vision loss from cataract and retinal involvement; progression supports the diagnosis’s pattern. Eye Disorders Database
7) Bedside hearing tests (Weber/Rinne). Quick tuning-fork tests suggest sensorineural loss, which is then confirmed with formal audiometry. Eye Disorders Database
8) Coordination task timing. Timed finger-tapping or peg tests quantify fine-motor slowing from cerebellar disease. PMC
9) Falls risk screen. Simple sit-to-stand and timed-up-and-go are practical ways to track mobility decline over time. PMC
10) Informant-based behavior scales. Short caregiver questionnaires document psychosis or apathy that often emerge later. PMC
C) Laboratory & pathological tests
**11) Genetic testing for ITM2B (BRI2). Sequencing confirms the characteristic 10-nucleotide duplication near the stop codon; this single test establishes the cause in families. PNAS
12) Targeted gene panels for hereditary CAA/dementia. Panels that include ITM2B help when the family story is unclear or there are overlapping features. PMC
13) CSF Alzheimer biomarkers (contextual). Aβ/tau profiles can help separate mixed pathology, since ADan vessels can also contain Aβ. Results guide counseling, not the core diagnosis. ScienceDirect
14) Pathology (biopsy or autopsy when available). Histology shows severe cerebral amyloid angiopathy with ADan (and often Aβ) deposits in vessel walls; special stains and antibodies confirm peptide identity. Oxford Academic
15) Research proteomics/peptidomics (specialized centers). Mass-spectrometry can directly identify ADan/ABri peptides in tissue—used mainly in research and select clinical labs. Oxford Academic
D) Electrodiagnostic tests
16) Pure-tone audiometry and brainstem auditory evoked responses. Quantify hearing loss and check neural conduction along auditory pathways. Eye Disorders Database
17) EEG (electroencephalogram). Looks for seizure activity or diffuse slowing when cognition fluctuates, especially after hemorrhage or microbleeds. PMC
18) Visual evoked potentials (VEP). Test optic-pathway conduction if vision loss seems greater than cataract alone. Eye Disorders Database
E) Imaging tests
19) MRI brain with susceptibility-weighted imaging (SWI/GRE). Shows microbleeds, superficial siderosis, and white-matter disease typical of CAA; helps track disease over time and hemorrhage risk. thejcn.com
20) CT head (acute) and retinal imaging (OCT/fundus). CT rapidly detects acute lobar hemorrhage. Retinal imaging documents vessel involvement paralleling brain CAA. PMCEye Disorders Database
Non-pharmacological treatments
Physiotherapy / rehabilitation & allied therapies
Gait and balance training (task-specific practice, cueing): reduces falls and improves mobility in cerebellar ataxia.
Coordination exercises (targeted limb accuracy drills): improves reach and daily tasks.
Core strengthening & postural therapy: stabilizes trunk for walking and speech breathing.
Vestibular rehab (gaze stabilization, habituation): eases imbalance/oscillopsia.
Assistive device assessment (cane/rollator; ankle-foot orthosis if needed): immediate fall-risk reduction.
Speech therapy (dysarthria): pacing, breath support, clear articulation; trains safe swallow strategies if needed.
Occupational therapy for ADL/IADL: home safety, energy conservation, adaptive tools (grab bars, shower chair).
Hand tremor strategies (weighted utensils, limb bracing): steadier self-care.
Low-vision rehabilitation: glare control, high-contrast lighting, magnifiers; orientation & mobility.
Hearing rehabilitation: hearing aids, remote microphones; communication training for family.
Falls-prevention program: home hazard audit, footwear, night-lights; community classes.
Aerobic conditioning (150 min/week as tolerated): supports brain/cardiovascular health.
Strength training (2–3 days/week): preserves function and reserve.
Flexibility & spasticity management: daily stretching, heat, gentle range of motion.
Fatigue management & sleep hygiene: set routines, treat sleep apnea if present.
Mind-body, “gene-informed,” and educational therapies
Genetic counseling (inheritance, testing choices, family planning, privacy). PMC
Advance-care and safety education (driving, work, finances, legal planning).
Stroke/bleeding risk teaching in CAA (blood-pressure goals, antithrombotic caution). NCBIMDPI
Medication literacy (high-risk drug review: anticoagulants, sedatives). MDPI
Cognitive rehabilitation (memory notebooks, spaced retrieval, external cues).
Caregiver skills training (communication, behavior strategies, respite).
Mind-body therapies (mindfulness, breathing, gentle yoga/taichi) for anxiety, sleep, balance.
Vision-specific education (UV protection, anti-glare lenses, contrast hacks).
Hearing conservation (noise avoidance, prompt treatment of ear infections).
Social support navigation (disability benefits, community rehab, rare-disease networks). GARD Information Center
Each item above: Purpose is to prevent avoidable harm and maintain independence; Mechanism is functional neurorehabilitation, vascular risk reduction, and environmental adaptation; Benefits include fewer falls, better communication, and lower caregiver burden.
Drug treatments
Levetiracetam (anti-seizure) – 500–1500 mg twice daily; for seizures/myoclonus; modulates synaptic release; may cause mood irritability/somnolence.
Lamotrigine (anti-seizure/mood) – titrate to 100–200 mg twice daily; stabilizes neuronal membranes; rash risk (rare SJS), dizziness.
Donepezil (AChE inhibitor) – 5–10 mg nightly; supports cholinergic tone for memory; GI upset, vivid dreams.
Rivastigmine (AChE inhibitor) – 1.5–6 mg twice daily or patch 4.6–13.3 mg/24 h; similar to above; nausea, weight loss.
Memantine (NMDA modulator) – 10 mg twice daily; reduces excitotoxicity; headache, dizziness.
Sertraline (SSRI) – 25–200 mg daily; treats depression/anxiety; GI upset, sexual side effects.
Citalopram/escitalopram (SSRI) – 10–20 mg daily / 5–20 mg daily; mood/anxiety; QT caution (citalopram).
Quetiapine (low-dose antipsychotic) – 12.5–25 mg at night, titrate cautiously for distressing psychosis; sedation, orthostasis; avoid routine use—use minimal effective dose.
Trazodone (sleep/behavior) – 25–100 mg at night; improves sleep; sedation, orthostasis.
Amantadine (ataxia/fatigue, off-label) – 100 mg 1–2×/day; dopaminergic/antiglutamatergic; insomnia, edema.
Buspirone (anxiety, adjunct) – 7.5–15 mg 2–3×/day; serotonergic; dizziness, nausea.
Propranolol (tremor) – 10–40 mg up to 3×/day; β-blockade; bradycardia, fatigue (avoid asthma).
Acetazolamide (periodic ataxia phenotype in some cerebellar disorders, selected trial) – 125–250 mg 1–2×/day; carbonic anhydrase inhibition; paresthesias, kidney stone risk.
Topical ocular therapy (short-term steroids/NSAIDs around cataract surgery as per ophthalmology) – dosing per surgeon; reduces inflammation; IOP rise/irritation possible.
Anti-VEGF intravitreal agents (retinal neovascular complications managed by a retina specialist): dosing per protocol; blocks pathologic vessel growth; risks include endophthalmitis/IOP spikes; often combined with laser photocoagulation. (This follows standard retina practice where neovascularization occurs; evidence in ADan specifically is limited—specialist judgment essential.) PubMed
Important safety notes (for CAA contexts): strict blood-pressure control helps outcomes; anticoagulants/antiplatelets are often avoided unless benefits clearly outweigh bleeding risk—this requires individualized, multidisciplinary decision-making. NCBIPMCMDPI
Dietary molecular supplements
Omega-3 fatty acids (EPA/DHA) 1–2 g/day – anti-inflammatory, vascular support.
Lutein + zeaxanthin (e.g., 10 mg + 2 mg/day) – macular pigment/anti-glare support for eyes.
Coenzyme Q10 100–300 mg/day – mitochondrial support; may aid fatigue.
Vitamin D3 1000–2000 IU/day (titrate to serum target) – neuro-immune & bone health.
Vitamin B12 if low or borderline (e.g., 1000 µg/day oral) – cognition/neuropathy prevention.
Magnesium L-threonate ~1–2 g/day (elemental Mg ~144 mg) – sleep/calm; watch GI effects.
Curcumin 500–1000 mg/day (enhanced-bioavailability forms) – antioxidant; drug interactions possible.
Resveratrol 100–300 mg/day – antioxidant/vascular; limited human CNS data.
N-acetylcysteine (NAC) 600–1200 mg/day – glutathione support; GI upset possible.
Probiotics/fiber – gut-brain and metabolic health.
(These support general eye-brain-vascular wellness; they do not remove ADan deposits.)
Immunity-booster / regenerative / stem-cell drugs
There are no approved immune, regenerative, or stem-cell drugs for ADan amyloidosis. Offering dosages would be unsafe and not evidence-based. Ongoing basic research explores: (1) reducing mutant BRI2 stress and enhancing ER-associated clearance (ERLAD), (2) targeting ADan/ABri aggregation, (3) restoring BRI2 synaptic function, and (4) general anti-CAA strategies—all still pre-clinical or early-stage without clinical dosing. Participation should only occur via regulated clinical trials. PMCNature
Safer near-term alternatives: optimize vascular risk, rehab, vision/hearing restoration, and family planning with genetic counseling.
Surgeries
Cataract extraction with intraocular lens – removes cloudy lens to improve vision and functionality; usually early in disease. Oxford Academic
Panretinal or focal laser photocoagulation (retinal neovascularization) – reduces bleeding risk and edema; specialist-guided. PubMed
Pars plana vitrectomy – clears non-resolving vitreous hemorrhage; restores media clarity. PubMed
Cochlear implant – for severe sensorineural hearing loss when hearing aids no longer help; improves speech understanding.
Tendon/orthopedic procedures for safety (select cases) – e.g., severe contracture or deformity management to aid mobility and reduce falls.
Preventions & protections
Blood-pressure control to guideline targets. NCBI
Avoid anticoagulants/antiplatelets unless clearly indicated; decide with neurology/cardiology. MDPI
Fall prevention (home safety, footwear, assistive devices).
Eye protection (UV-blocking lenses; prompt eye care).
Hearing conservation (limit loud noise; early amplification).
No smoking; limit alcohol.
Mediterranean-style diet; manage weight, sugar, and lipids.
Regular aerobic and strength exercise within safety limits.
Medication review (avoid sedatives when possible).
Family genetic counseling for at-risk adults. PMC
When to see doctors (red flags)
Sudden severe headache, new neurological deficit, collapse, or seizure → emergency care (possible bleed or seizure).
Sudden vision loss, many new floaters, or a “black curtain” → urgent retina evaluation.
Rapid behavior change, suicidal thoughts, or psychosis → urgent mental-health care.
New falls, choking, dramatic hearing/vision drops, or medication side effects → prompt clinic review.
Planning pregnancy or family testing → genetics appointment early.
What to eat and what to avoid
Eat more: vegetables, fruits, legumes, whole grains, fish, nuts, olive oil; calcium/vitamin-D sources; hydrating fluids.
Limit: salt (BP), added sugars, ultra-processed foods, trans-fats.
Avoid or strictly limit: tobacco, heavy alcohol, and unsupervised herbal “blood thinners” (ginkgo, high-dose fish oil) if bleeding risk is a concern—ask your clinician first.
For eyes: bright-light glare triggers → use hats/UV-blocking lenses; include leafy greens (lutein/zeaxanthin).
Frequently asked questions (FAQ)
Is ADan amyloidosis the same as Alzheimer’s?
No. Both have amyloid, but ADan comes from ITM2B/BRI2, not Aβ from APP. Clinical patterns and vessel involvement differ. NatureHow is it inherited?
Autosomal dominant: each child of an affected parent has a 50% chance of inheriting the mutation. Genetic counseling is key. PMCWhat usually appears first?
Early cataracts; later hearing loss, then ataxia and cognitive/psychiatric symptoms. Oxford AcademicCan cataracts be fixed?
Yes—cataract surgery often restores clarity, though other eye issues may still limit vision. Oxford AcademicIs stroke common in ADan?
Compared with other hereditary CAAs, overt lobar hemorrhage is reported less often, but vessel fragility exists—manage risk factors carefully. MedlinePlusAre there disease-modifying drugs?
None proven for ADan yet. Care is supportive; research focuses on BRI2/ADan biology and CAA mechanisms. PMCNatureShould I avoid blood thinners?
Often yes, unless there’s a strong reason (e.g., high-risk atrial fibrillation). Decisions are individualized with neurology/cardiology. PMCMDPIWhat imaging helps?
MRI with SWI to look for amyloid-related microbleeds; routine CT/MRI for acute symptoms. PMCCan hearing loss be treated?
Yes—hearing aids first; cochlear implant for severe cases after specialist assessment.Will seizures occur?
Some patients develop seizures/myoclonus; modern anti-seizure medicines are effective in many cases.Can lifestyle help?
Yes—BP control, exercise, Mediterranean diet, fall prevention, and sleep care support brain/vascular health. NCBIIs pregnancy safe?
Discuss preconception genetic counseling and maternal risk planning with neurology/obstetrics.What about clinical trials?
Ask at major academic centers; trials may target CAA or amyloid processing/clearance pathways (ADan-specific trials are rare). PMCHow common is this disease?
Extremely rare; first described in a Danish family; sporadic reports elsewhere. PNASWhat is the long-term outlook?
Course is slowly progressive over decades; early vision care, hearing rehab, fall prevention, and careful vascular management can meaningfully improve quality of life. Oxford AcademicNCBI
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 08, 2025.
